|
Patient, caregiver, and provider reported risk-benefit acceptance thresholds in non-muscle invasive bladder cancer (NMIBC) trial designs. |
| |
|
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health |
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med |
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Stock and Other Ownership Interests - CAPS Medical; Vessi Medical |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Cleveland Diagnostics; Fergene; Fergene; Merck; Nucleix; pacific edge; Photocure; Urogen pharma; Vessi Medical |
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst) |
| |
|
|
Consulting or Advisory Role - Fergene; Gerson Lehrman Group; Photocure |
Speakers' Bureau - Photocure |
Travel, Accommodations, Expenses - Photocure |
| |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; KDx Diagnostics; Photocure |
Research Funding - Photocure (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
|
Stock and Other Ownership Interests - Incyte |
Travel, Accommodations, Expenses - Incyte |
| |
|
|
Stock and Other Ownership Interests - Ferring |
Travel, Accommodations, Expenses - Ferring |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Chugai Pharma; Merck; QED Therapeutics |
| |
|
Honoraria - AstraZeneca (I); Tesaro (I) |
Consulting or Advisory Role - Abbott Molecular; Arquer Diagnostics; ArTara Therapeutics; Asieris Pharmaceuticals; AstraZeneca; BioClin Therapeutics; Bristol-Myers Squibb; Cepheid; CG Oncology; Eisai; EnGeneIC; Ferring; Imagin Medical; Janssen; MDxHealth; Medac; Merck; Pfizer; Photocure; Roviant Sciences; Seagen; Sesen Bio; Theralase; TMC Innovation; US Biotest |
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Merck; Photocure; SWOG |
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center |
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Baxter; BioCancell; Bristol-Myers Squibb; CG Oncology; Epivax Oncology; Ferring; FKD Therapies; Heat Biologics; Janssen; MDxHealth; Merck; Natera; Photocure; Roche/Genentech; Sesen Bio; Taris BioMedical; Telesta Therapeutics; UroGen pharma |
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; Photocure; Roche/Genentech; Taris BioMedical |
| |
|
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte |
Other Relationship - American Institutes for Research; Facing our Risk of Cancer Empowered; Facing our Risk of Cancer Empowered; Institute for Clinical and Economic Review; National Cancer Institute; National Cancer Institute; National Cancer Institute; SWOG; SWOG; University of Puerto Rico; University of Puerto Rico |